Disc Medicine, Inc. (IRON) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases.
Is Disc Medicine, Inc. stock overvalued or undervalued in 2026?
As of November 2, 2026, Disc Medicine, Inc. (IRON) trades at $78.62 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Disc Medicine, Inc.
Market cap $3B · 52 weeks $56 – $94 (16 % below the high) · P/E no earnings · Dividend none · Next earnings November 5, 2026 · expected EPS -$1.63 · Closing price, Nov 2 · accounts published Jul 30.
- Valuation: P/E — (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 4 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.0 %, fails.
- Market cap / Cash 3.5×, fails.
- Cash Runway 53 months, passes.
- Total Debt 0.0×, passes.
- Annual cash burn $5.11, info.
Against its peers (reference peers) — Disc Medicine, Inc.: P/E —; EV/EBITDA —; ROIC -38.2 %; $3.0B. Protagonist Therapeutics, Inc. (P/E 135×; EV/EBITDA 100×; ROIC 6.7 %; $9.0B), Telix Pharmaceuticals Limited (P/E 95.0×; EV/EBITDA 113×; ROIC -0.6 %; $3.1B), Nurix Therapeutics, Inc. (P/E 11.1×; EV/EBITDA 6.7×; ROIC 25.9 %; $2.8B).
Profitability
| Return on Equity | -37.17% |
| Return on Invested Capital | -38.19% |
| Return on Assets | -33.45% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.09 |
| Current Ratio | 24.14 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 24.37 |
Price Performance
| 1 month | +21.87% |
| 3 months | -0.37% |
| Year-to-date | -0.99% |
| 1 year | -7.17% |
| 3 years | +61.50% |
| 5 years | +105.27% |
Related companies: PTGX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of IRON: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks